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Abstract The identification of patients who will respond
to anti-tumor necrosis factor alpha (anti-TNF-a) therapy
will improve the efficacy, safety, and economic impact of
these agents. We investigated whether killer cell immu-
noglobulin-like receptor (KIR) genes are related to
response to anti-TNF-a therapy in patients with rheumatoid
arthritis (RA). Sixty-four RA patients and 100 healthy
controls were genotyped for 16 KIR genes and human
leukocyte antigen-C (HLA-C) group 1/2 using polymerase
chain reaction sequence-specific oligonucleotide probes
(PCR-SSOP). Each patient received anti-TNF-a therapy
(adalimumab, etanercept, or infliximab), and clinical
responses were evaluated after 3 months using the disease
activity score in 28 joints (DAS28). We investigated the
correlations between the carriership of KIR genes, HLA-C
group 1/2 genes, and clinical data with response to therapy.
Patients responding to therapy showed a significantly
higher frequency of KIR2DS2/KIR2DL2 (67.7% R vs.
33.3% NR; P = 0.012). A positive clinical outcome was
associated with an activating KIR–HLA genotype;
KIR2DS2?HLA-C group 1/2 homozygous. Inversely, non-
response was associated with the relatively inhibitory
KIR2DS2–HLA-C group 1/2 heterozygous genotype. The
KIR and HLA-C genotype of an RA patient may provide
predictive information for response to anti-TNF-a therapy.
Keywords Rheumatoid arthritis  Anti-TNF-alpha
therapy  Responder  Killer immunoglobulin-like
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Introduction
Chronic inflammatory conditions such as rheumatoid
arthritis are manifestations of inappropriate immune
responses, where activation and regulation are imbalanced.
Anti-inflammatory agents such as TNF-a antagonists
can achieve significant results; however, a subset of
patients do not respond. The current absence of clinically
useful predictors of response continues to impact both the
clinical management of patients and associated treatment
costs.
The KIR gene cluster, located on chromosome 19q13.4
[1], codes for a family of polymorphic receptors which can
be activating (KIR2DS/KIR3DS) or inhibiting (KIR2DL/
KIR3DL) in function. KIR are expressed on natural killer
(NK) cells and subsets of T-cells and modulate cell
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responses through recognition of human leukocyte antigen
(HLA) class I ligands on target cells.
Under normal conditions, inhibitory receptors
KIR2DL2 and KIR2DL3 recognize self-HLA-C1 ligands
and KIR2DL1 binds HLA-C2 ligands, acting to prevent
NK cell attack on normal cells. In the absence of these
inhibiting KIR-HLA signals, NK cell activation may
occur through activating receptors such as KIR2DS1 and
KIR2DS2 [2, 3]. It is the net balance of activating and
inhibiting signals from receptors such as KIR that
determine NK cell and T-cell reactivity. An individual’s
genotype predisposes to specific KIR/HLA interactions,
which may range from activating to relatively inhibitory
depending on which type of KIR and HLA is present
[4].
Specific KIR-HLA combinations have been associated
with differential responses to infection [5–7] and suscep-
tibility to autoimmune disorders including Crohn’s disease
[8–10], ulcerative colitis [10, 11], systemic lupus erythe-
matosus [12, 13], type I diabetes [14], and psoriatic arthritis
[15]. In the case of autoimmunity, the presence of an
activating KIR and/or absence of ligands for inhibitory
KIR is commonly associated with disease susceptibility.
In RA, activating KIR2DS2 has been shown to function
as a co-stimulatory molecule on CD4?CD28null T-cells
[16]. The expansion of this subset correlates with the
clinical phenotype of RA, where KIR2DS2 has been
associated with an increased likelihood for RA patients to
develop rheumatoid vasculitis [17–19].
These studies suggest a role for KIR in determining the
immune response in inflammatory disease, which prompts
the question of whether a particular KIR predisposition
could also influence response to anti-inflammatory
treatment.
In this study, we examined the KIR and HLA-C geno-
types of RA patients beginning anti-TNF-a treatment and
healthy controls. We found that the presence of KIR2DS2/
KIR2DL2 was significantly associated with patients who
responded to therapy. Further consideration of KIR with
HLA-C ligand availability indicated a potentially activat-
ing KIR–HLA-C genotype in responding patients relative
to non-responders to anti-TNF-a therapy.
Methods
Patients
Sixty-four unrelated Northern Irish chronic RA patients
were included in this study. Each subject was a patient
attending the rheumatology department of Musgrave Park
Hospital, Belfast, Northern Ireland. All patients fulfilled
the American College of Rheumatology 1987 revised
criteria for RA [20] and had active disease as indicated by a
DAS28 score of [3.2 [21].
There was no significant difference between the
responding and non-responding patients with respect to the
distribution of age (P = 0.21, unequal variance two-sided
t-test) or sex (P = 0.74, two-sided Fishers’ exact test).
Patients were assigned to anti-TNF-a treatment as part
of routine clinical practice. Each patient fulfilled the British
Society for Rheumatology (BSR) criteria for anti-TNF-a
therapy and had failed at least two disease-modifying anti-
rheumatic drugs (DMARDS) and had a DAS28 score of
[5.1 when originally assessed for treatment [22]. In some
cases, DAS28 scores between original assessment and
baseline treatment fluctuated, due to time lapsed from
assessment to treatment. Forty patients received ada-
limumab, 15 etanercept, and 9 infliximab. In most cases,
methotrexate (MTX) was maintained as a combination
therapy, and patients were allowed to continue oral glu-
cocorticoids. The main demographic and clinical features
of the patients are shown in Table 1. Thirty-eight patients
received a combination of MTX and anti-TNF-a drugs
(adalimumab, etanercept, or infliximab). There exists no
significant correlation between the anti-TNF-a drug and the
treatment outcome in those patients who received MTX
(P = 0.35, v2-test). In the group of patients who did not
receive MTX, we observed relatively more patients
responding to etanercept than to adalimumab (7 R and 1
NR vs. 8 R and 10 NR, P = 0.08, Fisher’s exact test).
Peripheral blood samples were collected from each
patient at time 0. Following 3 months of treatment, the
patients were assigned a responder or non-responder status,
according to the BSR criterion where clinical response is
defined as attaining a DAS28 score improvement of [1.2
or a DAS28 score of \3.2 [22].
A control population of 100 unrelated healthy Northern
Irish Caucasians were included for comparison of KIR
gene content. The healthy control blood samples were
collected at Northern Ireland Blood Transfusion Services,
Belfast. All participants in the study gave written informed
consent, and the study had local research ethical committee
approval from The Queens University, Belfast, Northern
Ireland.
Genotyping
Genomic DNA was extracted from peripheral blood lym-
phocytes using the salting-out method as previously
described [23]. DNA was typed for the presence or absence
of framework KIR genes: KIR2DL4, KIR3DL2, KIR3DL3,
and KIR3DP1, six activatory KIR (KIR2DS1, KIR2DS2,
KIR2S3, KIR2DS4, KIR2DS5 and KIR3DS1) and five
inhibitory KIR (KIR2DL1, KIR2DL2, KIR2DL3, KIR3DL1,
KIR2DL5). KIR2DP1 was also included in the typing. KIR
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genotyping was performed using the PCR primers and
probes of a KIR PCR-SSOP method [24]. Positive controls
of known KIR genotype, collectively incorporating all of
the KIR genes, were included in the typing procedure.
HLA-C typing was performed using the PCR-SSOP
method. DNA was amplified by PCR using the HLA-C
generic primers described by Cereb et al. [25]. A modified
version of the HLA-C typing method was used to define the
HLA-C1 and C2 groups using probe C293 and C291,
respectively [26].
Statistical methods and analysis
The significance of the differences in proportions of
responders and non-responders exhibiting a specific geno-
type was assessed using Fisher’s exact test. Welch’s t-
statistics and paired t-tests were used to investigate dif-
ferences in the DAS28 score. All tests were two-sided
unless otherwise stated. Adjustments for multiple testing
were made using Holm’s method.
Results
Within the group of 64 patients (described in Table 1), 34
were responders (53.0%) and 30 were non-responders
(47.0%). We compared the profiles of the KIR genes in the
groups of responders and non-responders to anti-TNF-a
therapy. In the responder population, the frequency of
KIR2DS2 and KIR2DL2 (which share high linkage dis-
equilibrium) was significantly higher compared with non-
responders (67.7% vs. 33.3%; P = 0.012, Fisher’s exact
test). To assess the relevance of the P-value and to reduce
the effect of multiple comparisons arising from testing a
family of 16 KIR genes, we performed a non-parametric
random permutation test as follows [27]. We randomly
permuted the class labels of all 64 patients and recomputed
the P-value for the difference in proportions of carriers/
non-carriers in responders and non-responders. We iterated
this procedure 10,000 times to generate the distribution of
P-values under the null hypothesis of no association
between the presence/absence of KIR2DS2/KIR2DL2 and
response to therapy. Among 100,000 permutation-based
P-values, only 1.17% are smaller than or equal to the
unpermuted P-value of 0.012. This confirms that carrier-
ship of KIR2DS2/KIR2L2 and the response to therapy
cannot be explained by chance alone.
There was no significant difference between the baseline
DAS28 score of patients carrying KIR2DS2/KIR2DL2 and
those who did not (P = 0.57, two-sided, unequal variance
t-test). The drug regime improved the DAS28 score in both
carriers (P = 0.005, paired t-test) and non-carriers of
KIR2DS2/KIR2DL2 (P \ 1.6 9 10-6, paired t-test). This
improvement, however, was significantly larger in patients
carrying KIR2DS2/KIR2DL2 (P = 0.04, two-sided,
unequal variance t-test).
When compared with healthy controls, the KIR2DS2/
KIR2DL2-positive genotype remained significantly more
frequent in the responder group (67.6% responders vs.
40.0% controls, P = 0.009). However, carriership of
KIR2DS2/KIR2DL2 in the non-responders was not signifi-
cantly different to healthy controls. The frequencies of all
other KIR genes tested were not significantly different
between responders, non-responders, or the healthy control
groups.
To consider the additional effect of HLA-C zygosity,
patients were categorized into four groups similar to a
psoriatic arthritis model proposed by Nelson et al. [15].
The genotype groups range from NK cell activating (group
I) to inhibiting (group IV) based on KIR-HLA interactions.
Nelson’s model considered the presence/absence of both
KIR2DS1 and KIR2DS2 with HLA-C zygosity. However,
since KIR2DS1 was not informative in our study, we
modified Nelson’s model to consider only KIR2DS2 in our
Table 1 Demographic and
clinical characteristics of
patients
Responders Non-responders All
Total 34 30 64
Mean age (years) 58 (range, 35–75) 54.53 (range, 27–73) 56.33 (range, 27–75)
Woman/man 28/6 26/4 54/10
MTX and adalimumab 9 13 22
MTX and etanercept 5 2 7
MTX and infliximab 5 4 9
Adalimumab 8 10 18
Etanercept 7 1 8
Infliximab 0 0 0
Mean pre-DAS28 score 6.21 (range, 4.08–8.96) 5.43 (range, 3.75–7.38) 5.85 (range, 3.75–8.96)
Mean post-DAS28 score 3.64 (range, 1.18–6.15) 5.61 (range, 3.49–7.27) 4.53 (range, 1.18–7.27)
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interpretation. Thus, the most activating genotype, group I,
included patients who were positive for activating
KIR2DS2 and were HLA-C homozygous (C1/C1 or C2/C2).
Such HLA-C homozygosity limits ligand availability for
inhibitory KIR (KIR2DL1 or KIR2DL2/KIR2L3), restrict-
ing counteracting inhibition signals. Patients in group II
were KIR2DS2 positive and were HLA-C heterozygous
(i.e., they had both ligands C1/C2 and therefore relatively
more inhibitory receptor functionality due to ligand avail-
ability). Group III patients were KIR2DS2 negative and
HLA-C homozygous (without the activating receptor
KIR2DS2 but limited inhibitory function through homo-
zygosity for the HLA-C ligands of inhibitory KIR). Finally,
the most inhibitory genotype group IV patients were
KIR2DS2 negative and HLA-C heterozygous. Group IV
patients are predisposed to a more inhibiting genotype
since they lack KIR2DS2 and carry both HLA-C ligand
types, promoting function of all corresponding inhibitory
KIR receptors.
We observed that the ratio of responders to non-
responders inverts from groups I to IV (Fig. 1).
A groupwise comparison of the number of responders
and non-responders revealed a significant difference
between groups I and IV (P = 0.015, adjusted for multiple
comparisons using Holm’s correction). No other groupwise
comparison revealed a significant difference.
There was no significant difference between the groups
with respect to the DAS28 score before therapy. The
majority of patients in groups I to III experienced a sig-
nificant reduction in the DAS28 score after treatment
(P = 0.004, P = 0.004, and P = 0.033, respectively,
based on paired t-test with Holm’s correction), whereas
patients in group IV did not (P = 0.161). Table 2 sum-
marizes the DAS28 scores at baseline, 3 months after
therapy, and the improvements in groups I and IV. The
mean DAS28 score improvement for patients in group I
was significantly larger than that of group IV (P = 0.022).
These results suggest that there exist subgroups of
patients characterized by distinct KIR and HLA-C geno-
type profiles that are associated with a significant differ-
ence of response to anti-TNF-a therapy.
Discussion
The influence of the KIR genes in inflammatory disease is
supported by a growing body of evidence demonstrating
the association of specific KIR genotypes with disease.
Further consideration of the cumulative effect of KIR
with HLA ligand availability permits differentiation of
subjects to relatively activating or inhibiting genotypes,
which ultimately influence the responses of KIR-express-
ing cells.
The promotion or prevention of NK cell activation
crucially influences innate defences, the facilitation of
cross talk between cells, and adaptive immunity. NK cell
importance in immune regulation is reflected through their
interaction with components of the adaptive immune sys-
tem where they have been shown to eradicate autoreactive
T-cells and B-cells [28].
In this study, a KIR-HLA combination that favors NK
cell activation through the presence of activating KIR2DS2
and homozygosity for HLA-C1 or HLA-C2 was associated
with responders to anti-TNF-a. Historically, NK cell
activity in the peripheral blood of RA patients has been
reported to be normal [29, 30] or low [31–33]. It is possible
that responders could have a different mechanism of dis-
ease pathogenesis than non-responders, and it would be
interesting to investigate NK cell activity in both groups.
The occurrence of an inhibitory profile of NK cells in non-
responders is supported by their prevalence in the proposed
group IV cohort that are KIR2DS2 negative and HLA-C
heterozygous. The general inversion of the numbers of
responders and non-responders moving through groups I to
IV, perhaps speaks to the continuum of excellent to poor
responders observed in clinical practice. In this model,
determination of where those patients who gain responses
Fig. 1 Number of responders (white) and non-responders (black) in
the groups I to IV. Groups range from most activating to most
inhibiting from groups I to IV, respectively. Patients included in
group I are KIR2DS2 positive and HLA-C group 1/2 homozygous
(C1/C1 or C2/C2). Group II patients are KIR2DS2 positive and HLA-
C group 1/2 heterozygous (C1/C2). Group III patients are KIR2DS2
negative and HLA-C group 1/2 homozygous. Group IV patients are
KIR2DS2 negative and HLA-C group 1/2 hetrozygous
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from up-dosing or switching anti-TNF-a therapy are posi-
tioned would also be of interest.
Our study has several limitations that impact the inter-
pretation of these findings. In this small cohort of 64 sub-
jects, we provide preliminary data suggesting a possible
role for a KIR–HLA-C genotype in response to anti-TNF-a
therapy. These findings will require independent validation
in a larger population, which will permit further sub-
analysis of KIR–HLA-C genotype and response for each
anti-TNF-a therapy.
KIR2DS2 has been associated with vascular complica-
tions of RA [16, 18, 19] and with numerous inflammatory
conditions and autoimmune outcomes [11, 13–15, 34, 35].
It is therefore not surprising that this activating KIR is
implemented in response to anti-inflammatory therapy. It
could be argued that patients carrying KIR2DS2 may be
subject to a greater disease severity and hence are likely to
show a more robust response to therapy. In this study, the
baseline DAS28 scores of responders were significantly
higher than those of non-responders, but this could not be
attributed to carriership of KIR2DS2. The baseline DAS28
scores for patients with and without KIR2DS2 were not
statistically different; however, the improvement of the
score was significantly larger in the group of patients car-
rying this gene.
In previous reports, inflammatory cytokine polymor-
phisms such as TNF-a –308G/A have indicated that a
genetic predisposition toward increased TNF-a expression
can be associated with non-response [36–39], These find-
ings have been disputed in a recent meta-analysis by Pavy
et al. [40], and so, the role of this SNP remains unclear.
A gene expression study of baseline synovial tissue
indicated an upregulation of inflammation-related genes in
patients who responded to infliximab [41]. In proteomics, a
baseline 24-protein signature of elevated serum antibody
and cytokine concentrations is reported in RA patients who
responded to etanercept [42]. Alternatively, Badot et al.
[43] related non-responders to adalimumab with overex-
pression of cell division and immune regulation genes.
These studies and our current study point to a possible
activating profile that may provide an advantage for
response to anti-TNF-a therapy.
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